Wanming Saibo

Wanming Saibo is a Beijing-based biotechnology company specializing in the development of next-generation RNA therapeutics, with a core focus on circular RNA (circRNA) technology. Founded in 2021, the company leverages its proprietary platform to design RNA molecules that offer superior stability and longer-lasting protein expression compared to traditional linear mRNA. Its research and development efforts are primarily directed toward infectious disease vaccines, cancer immunotherapy, and protein replacement therapies for rare diseases. Backed by prominent investors such as GL Ventures and Sequoia China, Wanming Saibo is advancing a pipeline of preclinical candidates aimed at addressing significant unmet medical needs through innovative RNA engineering.